Wie hoch ist der Preis für Alimera Sciences, Inc. (ALIM)

Preis für Alimera Sciences, Inc. (ALIM) ist $5.54

Wie hoch ist die Marktkapitalisierung für Alimera Sciences, Inc. (ALIM)

Marktkapitalisierung für Alimera Sciences, Inc. (ALIM) ist $38.76M

Alimera Sciences, Inc. (ALIM) Aktiensplits

Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.

Jahr	Aktien-Split	Multiplikator	Kumulierter Multiplikator
2019-11-15	1:15	x0.066666666666667	x0.066666666666667

Jahr

Aktien-Split

Multiplikator

Kumulierter Multiplikator

2019-11-15

1:15

x0.066666666666667

Unternehmen	Anzahl der Aktiensplits	Kumulierter Multiplikator	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	0	-	DE
Merck KGaA MRK.DE	0	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0	-	JP
Galderma Group AG GALD.SW	0	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	5	x119	IN

Unternehmen

Anzahl der Aktiensplits

Kumulierter Multiplikator

Land